Earningsreport

Q2/2023 6/30/2023 EPS -0.840 ZacksConsensus -0.920 ActVsEst 0.080 - Beat

Relmada Therapeutics, Inc.  (RLMD) 
NASDAQ:AMEX Investor Relations: ir.relmada.com